Karyopharm Therapeutics Inc.KPTI
Price (close)
$1.73
Market cap
$39.2M
P/E
—
Revenue (TTM)
$146.6M
Net income
-$224.7M
Dividend yield
—
1-year total return
-74.0%
Net margin
-153.3%
Revenue growth
6.8%
Debt / equity
—
What Karyopharm Therapeutics Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $108.1M | $209.8M | $157.1M | $146.0M | $145.2M | $146.1M |
| Net income | -$196.3M | -$124.1M | -$165.3M | -$143.1M | -$76.4M | -$196.0M |
| Free cash flow | -$160.4M | -$107.3M | -$149.7M | -$92.7M | -$127.6M | -$75.4M |
More on KPTI.
- Karyopharm Therapeutics Inc. summary
- Karyopharm Therapeutics Inc. financial statements
- Karyopharm Therapeutics Inc. key metrics
- Karyopharm Therapeutics Inc. health scores and style box
- Karyopharm Therapeutics Inc. earnings
- Karyopharm Therapeutics Inc. dividends
- Karyopharm Therapeutics Inc. valuation
- Karyopharm Therapeutics Inc. ownership and insiders
- Karyopharm Therapeutics Inc. peers
Figures from Karyopharm Therapeutics Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.